Senores Pharmaceuticals (NSE:SENORES) Ending Cash Position: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
19 GF Score
Price ₹1,428.40
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals Ending Cash Position?

Senores Pharmaceuticals NSE:SENORES -0.14% 19 Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

Senores Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 was ₹0 Mil.

Senores Pharmaceuticals's annual Ending Cash Position increased from Mar. 2024 (₹77 Mil) to Mar. 2025 (₹1,054 Mil) but then declined from Mar. 2025 (₹1,054 Mil) to Mar. 2026 (₹456 Mil).

Senores Pharmaceuticals Ending Cash Position Related Terms

Senores Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Ending Cash Position Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
32.15 1.00 76.50 1,053.80 455.50

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SENORES
19GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Senores Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1053.9+-598.4
=456

Senores Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0 Mil mean?
Senores Pharmaceuticals (NSE:SENORES) has a Ending Cash Position of ₹0 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' Ending Cash Position too high?
Senores Pharmaceuticals' current Ending Cash Position is ₹0 Mil. Overall, Senores Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Ending Cash Position compare to LLY and JNJ?
Senores Pharmaceuticals' Ending Cash Position of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current Ending Cash Position is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Ending Cash Position of ₹0 Mil. The current Ending Cash Position is ₹0 Mil. Senores Pharmaceuticals' overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
19GF Score

Get the complete analysis for NSE:SENORES

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,428.40
Price